First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

被引：43
|
作者：
Kopetz, S.
Mita, M. M.
Mok, I.
Sankhala, K. K.
Moseley, J.
Sherman, B. M.
Bradley, C. R.
Tolcher, A. W.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
[3] BiPar Sci, Brisbane, CA USA
[4] S Texas Accelerated Res Therapeut, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3577
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    Lotte van Andel
    Z. Zhang
    S. Lu
    V. Kansra
    S. Agarwal
    L. Hughes
    M. M. Tibben
    A. Gebretensae
    L. Lucas
    M. J. X. Hillebrand
    H. Rosing
    J. H. M. Schellens
    J. H. Beijnen
    Investigational New Drugs, 2017, 35 : 751 - 765
  • [42] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    van Andel, Lotte
    Zhang, Z.
    Lu, S.
    Kansra, V.
    Agarwal, S.
    Hughes, L.
    Tibben, M. M.
    Gebretensae, A.
    Lucas, L.
    Hillebrand, M. J. X.
    Rosing, H.
    Schellens, J. H. M.
    Beijnen, J. H.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 751 - 765
  • [43] Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors.
    LoRusso, P.
    Ji, J. J.
    Li, J.
    Heilbrun, K.
    Shapiro, G.
    Sausville, E. A.
    Boerner, S. A.
    Smith, D. W.
    Pilat, M. J.
    Zhang, J.
    Chen, A. P.
    Nechiporchik, N.
    Parchment, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
    Kummar, Shivaani
    Kinders, Robert
    Gutierrez, Martin E.
    Rubinstein, Larry
    Parchment, Ralph E.
    Phillips, Lawrence R.
    Ji, Jiuping
    Monks, Anne
    Low, Jennifer A.
    Chen, Alice
    Murgo, Anthony J.
    Collins, Jerry
    Steinberg, Seth M.
    Eliopoulos, Helen
    Giranda, Vincent L.
    Gordon, Gary
    Helman, Lee
    Wiltrout, Robert
    Tomaszewski, Joseph E.
    Doroshow, James H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2705 - 2711
  • [45] Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis
    Gong, Han
    Nie, Dan
    Huang, Yue
    Li, Zhengyu
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (10) : 1576 - 1582
  • [46] First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).
    Plummer, R.
    Lorigan, P.
    Evans, J.
    Steven, N.
    Middleton, M.
    Wilson, R.
    Snow, K.
    Dewji, R.
    Calvert, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 456S - 456S
  • [47] Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?
    Ali, Majid
    Telfer, Brian A.
    McCrudden, Cian
    O'Rourke, Martin
    Thomas, Huw D.
    Kamjoo, Marzieh
    Kyle, Suzanne
    Robson, Tracy
    Shaw, Chris
    Hirst, David G.
    Curtin, Nicola J.
    Williams, Kaye J.
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6106 - 6112
  • [48] First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors
    Camacho, L. H.
    Moulder, S. L.
    LoRusso, P. M.
    Blumenschein, G. R.
    Bristow, P. J.
    Kurzrock, R.
    Fu, S.
    Schlienger, K.
    Bergstrom, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 with antitumour activity in advanced BRCA-deficient and sporadic cancers
    Garcia, V. M. Moreno
    Wilding, G.
    Sandhu, S. K.
    Schelman, W. R.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Kreischer, N.
    Carpenter, C.
    Molife, L. R.
    Kaye, S.
    de Bono, J. S.
    Wenham, R. M.
    ANNALS OF ONCOLOGY, 2011, 22 : 39 - 39
  • [50] Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
    Dumbrava, Ecaterina Elena
    Shapiro, Geoffrey
    Bendell, Johanna C.
    Yap, Timothy A.
    Jeselsohn, Rinath
    Lepley, Denise M.
    Hurley, Sabrina
    Lin, Kevin K.
    Liao, Michelle
    Habeck, Jenn
    Enke, Aaron
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345